JNJ | Weekly | Haru Insights

Johnson & Johnson delivered a second-quarter 2026 earnings beat with 6.6% revenue growth and 4.7% earnings growth, driven by strong performance in its Innovative Medicine segment and continued success of blockbuster drugs like Darzalex and Tremfya, while also generating $240.7 million in royalty revenue from Halozyme’s ENHANZE platform.
JNJ received FDA approval for its OTTAVA™ Robotic Surgical System, marking a pivotal strategic entry into the high-stakes robotic surgery market, with commercial rollout planned in Japan and Europe and U.S. launch pending urology indication clearance—a major step in its MedTech evolution and innovation drive.

JNJ’s innovative momentum, fueled by blockbuster drugs and new product launches like Inlexzo and Imaavy, is successfully countering the Stelara patent cliff and ensuring sustainable revenue growth.
The $240 million+ in Q1 2026 royalty revenue from Halozyme’s ENHANZE platform confirms a scalable, high-margin business model that turbocharges R&D efficiency and validates JNJ’s strategic licensing approach.
The $3.05 billion acquisition of Halda Therapeutics marks JNJ’s most aggressive bet on gene therapy—signaling transformative ambition and positioning it at the frontier of next-generation medicine.
JNJ’s 64-year dividend streak and 2.14% yield, underpinned by a conservative 49% payout ratio, reinforce its status as a fortress-like income stock, drawing long-term capital in uncertain markets.
The FDA approval of OTTAVA™ reflects JNJ’s deepening capability in MedTech innovation and sets the stage for a bold new chapter beyond traditional pharmaceuticals.

Johnson & Johnson (JNJ)[Tv]